VivoSeq
Other

Interstitial Cystitis

63

Pipeline Programs↗

8

Active Trials↗

35

Companies Involved↗

Interstitial Cystitis is a moderately active landscape with 63 programs across 35 companies. The most active players are Imbrium Therapeutics, Trillium Therapeutics Inc., Jazz Pharmaceuticals. 13 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

0/100

Mech. Concentration

9/100

Completion Rate

63/100

Attrition Rate

28/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Imbrium Therapeutics

1 program

Phase 1T

Trillium Therapeutics Inc.

1 program

Phase 1Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Phase 1Bayer logo

Bayer

1 program

Phase 1A

Azurity Pharmaceuticals

1 program

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

65 of 71 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody57%Cell therapy11%

Small molecule leads; the ring shows all 71 classified programs, each share of the total. Modality classified for 100% of 73 pipeline programs.

Analysis

Trial Status

69

clinical trials

Completed33 · 48%
Terminated14 · 20%
Unknown status9 · 13%
Recruiting7 · 10%
Withdrawn5 · 7%
Active, not recruiting1 · 1%

Clinical Trials

Trial Activity

69 trials

Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
Recruiting·VVaneltix Pharma, Inc.·Phase 2·NCT06394830·50 enrolled
The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis With Hunner's Lesions
Recruiting·JJSC NextGen·Phase 2/3·NCT07459790·180 enrolled
Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis
Recruiting·TThe Foundation for Orthopaedics and Regenerative Medicine·Phase 1·NCT05147779·20 enrolled
Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis
Recruiting·WWake Forest University Health Sciences·Phase 1·NCT04734106·30 enrolled
Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome
Recruiting·—·Phase 2/3·NCT06096597·100 enrolled
The Study is Being Conducted to Find a New Treatment for Patients Suffering From Interstitial Cystitis Without Hunner's Lesions.
Recruiting·JJSC NextGen·Phase 2/3·NCT07391306·180 enrolled
Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome
Recruiting·UUniversity of Louisville·Phase 1/2·NCT04845217·100 enrolled
Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome
Active, not recruiting·SStanford University·Phase 1·NCT05485207·5 enrolled
Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome
Completed·WWatson Pharmaceuticals·Phase 2·NCT00919113·98 enrolled
Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis
Completed·MMediciNova·Phase 2·NCT00295854·296 enrolled
Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain
Completed·CCitrus Valley Medical Research, Inc.·Phase 4·NCT02000401·15 enrolled
Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action
Completed·TThe Cleveland Clinic·Phase 2·NCT01990898·26 enrolled
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Completed·AbbVie logoAbbVie·Phase 2·NCT05141006·83 enrolled
Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome
Completed·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 3·NCT01294878·3 enrolled
A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
Completed·Astellas logoAstellas·Phase 2·NCT03282318·119 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)